Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.

July 11, 2025

Vol.51 No.27

Drugs & Targets

China’s NMPA approves lisaftoclax for CLL or SLL

The National Medical Products Administration in China approved lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors.

July 11, 2025

Vol.51 No.27

Podcast

In The Headlines: George Weiner on the importance of patients’ stories

In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.

July 09, 2025

Vol.51 No.26

Clinical Roundup

Duvelisib + romidepsin combination effective for T-cell lymphoma patients, Mass General Brigham study shows

Relapsed/refractory peripheral and cutaneous T-cell lymphomas are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell transplants, but the disease needs to be brought under control before patients can undergo this treatment.

June 27, 2025

Vol.51 No.25

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

YOU MAY BE INTERESTED IN

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

China’s NMPA approves lisaftoclax for CLL or SLL

In The Headlines: George Weiner on the importance of patients’ stories

Duvelisib + romidepsin combination effective for T-cell lymphoma patients, Mass General Brigham study shows

Renew today!

Subscriber content

Never miss an issue!

Login